Background: The risk of late recurrence after venous thromboembolism (VTE) related to weak transient risk factors (RFs) in young women guides thromboprophylaxis.
Objective: To estimate the incidence of recurring VTE in untreated women with a first episode due to combined oral contraceptives (COCs), pregnancy-puerperium, minor trauma-fracture, brief surgery, infection or brief immobility.
Methods: We performed a multicentre, international, observational, retrospective study on women aged 18-55 years old, free from high-risk thrombophilia and subsequently monitored.
Background: In young women with venous thromboembolism (VTE) related to weak transient risk factors, it remains unknown whether stress levels and intimate partner violence (IPV) are associated with recurrence. The VTE-WEAK study aims to investigate the association between perceived stress and IPV with a recurrence of VTE in women with a first episode of VTE due to combined oral contraceptives, pregnancy-puerperium, minor trauma/fracture, brief surgery, infection or brief immobility, and not using antithrombotic prophylaxis.
Material And Methods: We performed a multicenter, international, observational, retrospective study on women referred for thrombophilia screening who were subsequently monitored.
Background: Intimate partner violence (IPV) targeting women is probably underestimated during a woman's lifetime. Venous thromboembolism (VTE) is a multifactorial disease associated with haemostasis-activating conditions. Minor injuries can trigger VTE.
View Article and Find Full Text PDFIntroduction: Limitations in the data used to define thromboprophylaxis for patients with antiphospholipid antibodies (aPLAbs) and thrombosis include uncertainties after an initial provoked venous thromboembolic event (VTE). We aimed to study such cases associated with combined oral contraceptive (COC) intake.
Methods: We retrospectively analysed thrombotic outcomes after a first COC-associated VTE and positive aPLAbs, with a low risk HERDOO2 score, on low-dose aspirin (LDA) secondary thromboprophylaxis, seen from 2010 to 2021 in 3 tertiary referral centres, one in France and 2 in Russia.